Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial

PURPOSE: Safe, effective treatments are needed for pediatric patients with chronic myeloid leukemia in chronic phase (CML-CP). Dasatinib is approved for treatment of adults and children with CML-CP. A phase I study determined suitable dosing for children with Philadelphia chromosome–positive (Ph+) l...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Gore, Lia, Kearns, Pamela R., de Martino, Maria Lucia, Lee, De Souza, Carmino Antonio, Bertrand, Yves, Hijiya, Nobuko, Stork, Linda C., Chung, Nack-Gyun, Cardos, Rocio Cardenas, Saikia, Tapan, Fagioli, Franca, Seo, Jong Jin, Landman-Parker, Judith, Lancaster, Donna, Place, Andrew E., Rabin, Karen R., Sacchi, Mariana, Swanink, Rene, Zwaan, C. Michel
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2018
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5929218/
https://ncbi.nlm.nih.gov/pubmed/29498925
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.75.9597
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi